Your browser doesn't support javascript.
loading
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan.
Matsumura, Noriomi; Mandai, Masaki.
Affiliation
  • Matsumura N; Faculty of Medicine, Kindai University, Osaka-Sayama, Japan. noriomi@med.kindai.ac.jp.
  • Mandai M; Editorial Committee, Japan Society of Clinical Oncology, Tokyo, Japan. noriomi@med.kindai.ac.jp.
Int J Clin Oncol ; 29(7): 863-864, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38687406
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Drug Approval / Multiple Myeloma Limits: Female / Humans Language: En Journal: Int J Clin Oncol / Int. j. clin. oncol / International journal of clinical oncology Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Drug Approval / Multiple Myeloma Limits: Female / Humans Language: En Journal: Int J Clin Oncol / Int. j. clin. oncol / International journal of clinical oncology Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication: